Noxopharm initiates Phase Ib trial of NOX66 for prostate cancer
Australia-based Noxopharm has initiated a Phase Ib clinical trial of NOX66 in metastatic castrate-resistant prostate cancer patients who do not have remaining standard therapeutic options.
Mohd M. M. Hanafi, Adlin Afzan, Harisun Yaakob, Ramlan Aziz, Mohamad R. Sarmidi, Jean-Luc Wolfender, Jose M. Prieto
Alessia Cimadamore, Silvia Gasparrini, Roberta Mazzucchelli, Andrea Doria, Liang Cheng, Antonio Lopez-Beltran, Matteo Santoni, Marina Scarpelli, Rodolfo Montironi
This study evaluated the effects of the luteinizing hormone-releasing hormone agonist therapy leuprorelin acetate (LA) on anxiety and quality of life (QoL) over time in men with PCa. METHODS: This observational, non interventional, multicenter study was conducted in France. Patients with PCa eligible for therapy with a 6-month LA depot were enrolled. Patients completed questionnaires assessing anxiety (memorial anxiety scale for prostate cancer [MAX-PC] ; state trait anxiety inventory [STAI]) and QoL (medical outcomes study 12-item short-form health survey [SF-12] physical summary component [PCS] and mental compon...
Authors: Saad F Abstract Since the early 1990s, it has been recognized that testosterone (T) levels are lower in men with type 2 diabetes mellitus (T2DM) compared with nondiabetic men (controls). Hypogonadism has been reported in approximately 50% of men with T2DM with robust correlations with measures of obesity, such as waist circumference and body mass index (BMI). In longitudinal studies, hypogonadism has been identified as a predictor of incident T2DM. Experimental withdrawal of T led to acute decreased insulin sensitivity, which can be reversed by normalization of T concentrations. Androgen deprivation therap...
BackgroundWhile histopathological evaluation remains the gold standard for diagnosis of prostate cancer (PCa), sampling errors remain a frequent problem; therefore, use of tissue biomarkers that can distinguish between benign and malignant prostate disease is a potentially beneficial diagnostic strategy. MethodsDeep sequencing of the miRNA transcriptome of 14 benign prostatic hyperplasia (BPH) and 60 cancerous and non‐cancerous prostate samples extracted from 34 cancer‐bearing prostates removed by prostatectomy was performed; of the latter 60 samples, 16, 21, and 23 samples contained 30%, and no dysplastic cells, respe...
Condition: Bony Metastases From Castrate Refractory Prostate Cancer Intervention: Drug: Radium-223 dichloride Sponsor: The University of Texas Health Science Center, Houston Recruiting
Conditions: Prostate Adenocarcinoma; Stage IIB Prostate Cancer AJCC v7; Stage III Prostate Cancer AJCC v7; Stage IV Prostate Cancer AJCC v7 Interventions: Procedure: Computed Tomography; Radiation: Gallium Ga 68-labeled PSMA-11; Other: Laboratory Biomarker Analysis; Procedure: Positron Emission Tomography Sponsors: Jonsson Comprehensive Cancer Center; National Cancer Institute (NCI) Recruiting
Condition: Stage II Prostate Adenocarcinoma Interventions: Radiation: Intensity-Modulated Radiation Therapy (IMRT); Radiation: Stereotactic Body Radiation Therapy (SBRT) Sponsors: NRG Oncology; National Cancer Institute (NCI) Not yet recruiting
The European Medicines Agency ’s Pharmacovigilance Risk Assessment Committee has begun two new safety-related referrals
(University of Southern California - Health Sciences) A new study from Keck Medicine of USC finds that data from a novel recorder can be used to objectively measure surgeons' proficiency in robotic-assisted prostate cancer surgery.